

Tom J Snijders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7591477/publications.pdf>

Version: 2024-02-01

54
papers

1,325
citations

361413

20
h-index

395702

33
g-index

56
all docs

56
docs citations

56
times ranked

2072
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment. <i>Journal of Neuro-Oncology</i> , 2017, 134, 9-18.	2.9	126
2	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	3.5	112
3	Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 140, 485-496.	2.9	95
4	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019, 21, 648-658.	1.2	90
5	Prognostic relevance of epilepsy at presentation in glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 700-706.	1.2	70
6	Stability of a chronic implanted brain-computer interface in late-stage amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2019, 130, 1798-1803.	1.5	49
7	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. <i>Investigational New Drugs</i> , 2016, 34, 184-192.	2.6	46
8	Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial. <i>Journal of Neuro-Oncology</i> , 2018, 137, 191-203.	2.9	46
9	Preventing inflammation inhibits biopsy-mediated changes in tumor cell behavior. <i>Scientific Reports</i> , 2017, 7, 7529.	3.3	39
10	Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment. <i>Neuro-Oncology Practice</i> , 2019, 6, 463-472.	1.6	38
11	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 127, 56-65.	4.4	36
12	MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 974-977.	2.5	35
13	Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. <i>British Journal of Haematology</i> , 2018, 182, 384-403.	2.5	33
14	Current treatment of low grade gliomas. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 223-227.	0.5	31
15	Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies. <i>Clinical Nutrition</i> , 2019, 38, 1986-1994.	5.0	31
16	Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates. <i>PLoS ONE</i> , 2019, 14, e0222717.	2.5	28
17	Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2020, 146, 97-109.	2.9	28
18	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Prevalence and predictors of unexplained neurological symptoms in an academic neurology outpatient clinic. <i>Journal of Neurology</i> , 2004, 251, 66-71.	3.6	27
20	Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis. <i>BMC Neurology</i> , 2014, 14, 152.	1.8	24
21	Dose-dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 35-41.	1.7	24
22	Myeloid sarcoma presenting as a recurrent, multifocal nerve root entrapment syndrome. <i>Journal of Neuro-Oncology</i> , 2009, 91, 59-62.	2.9	23
23	Cognitive impairments are independently associated with shorter survival in diffuse glioma patients. <i>Journal of Neurology</i> , 2021, 268, 1434-1442.	3.6	20
24	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
25	Effect of radiation therapy on cerebral cortical thickness in glioma patients: Treatment-induced thinning of the healthy cortex. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa060.	0.7	17
26	CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [⁶⁸ Ga]Ga-Pentixafor / [¹⁷⁷ Lu]Lu-Pentixather. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 481-491.	6.4	17
27	Attentional modulation fails to attenuate the subjective pain experience in chronic, unexplained pain. <i>European Journal of Pain</i> , 2010, 14, 282.e1-10.	2.8	15
28	Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa044.	0.7	15
29	Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with ¹⁰ brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2019, 138, 173-179.	0.6	13
30	Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma—Multivariable Analysis of 497 Patients. <i>World Neurosurgery</i> , 2019, 126, e1081-e1091.	1.3	13
31	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 406-409.	5.0	13
32	Epilepsy Associates with Decreased HIF-1 α /STAT5b Signaling in Glioblastoma. <i>Cancers</i> , 2019, 11, 41.	3.7	12
33	Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma. <i>Neuro-Oncology</i> , 2022, 24, 1660-1670.	1.2	12
34	Length of Thromboprophylaxis in Patients Operated on for a High-Grade Glioma: A Retrospective Study.. <i>World Neurosurgery</i> , 2018, 115, e723-e730.	1.3	10
35	The man who lost his body: Suboptimal multisensory integration yields body awareness problems after a right temporoparietal brain tumour. <i>Journal of Neuropsychology</i> , 2019, 13, 603-612.	1.4	10
36	Molecular tools for the pathologic diagnosis of central nervous system tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 4-16.	1.6	8

#	ARTICLE	IF	CITATIONS
37	High frequency oscillations associate with neuroinflammation in low-grade epilepsy associated tumors. <i>Clinical Neurophysiology</i> , 2021, , .	1.5	8
38	Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities. <i>Journal of Neurology</i> , 2012, 259, 1231-1233.	3.6	7
39	Perfusion imaging with arterial spin labeling (ASL)â€“MRI predicts malignant progression in lowâ€“grade (WHO grade II) gliomas. <i>Neuroradiology</i> , 2021, 63, 2023-2033.	2.2	7
40	Symptom Monitoring in Glioma Patients: Development of the Edmonton Symptom Assessment System Glioma Module. <i>Journal of Neuroscience Nursing</i> , 2018, 50, 381-387.	1.1	6
41	Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz032.	0.7	6
42	Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz025.	0.7	6
43	Glioblastomas within the Subventricular Zone Are Region-Specific Enriched for Mesenchymal Transition Markers: An Intratumoral Gene Expression Analysis. <i>Cancers</i> , 2021, 13, 3764.	3.7	6
44	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. <i>Neuro-Oncology</i> , 2022, 24, 326-328.	1.2	5
45	Added Value of Cognition in the Prediction of Survival in Low and High Grade Glioma. <i>Frontiers in Neurology</i> , 2021, 12, 773908.	2.4	5
46	Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 851803.	2.8	4
47	Reactivity in Painâ€“Free Subjects and a Clinical Pain Population: Evaluation of the <sc>K</sc>ohn Reactivity Scaleâ€“<sc>D</sc>utch Version. <i>Pain Practice</i> , 2013, 13, 459-466.	1.9	3
48	Conventional MRI Criteria to Differentiate Progressive Disease from Treatment-Induced Effects in High-Grade (WHO Grade 3â€“4) Gliomas. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200359.	1.1	3
49	Treatment of anaplastic gliomas. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 621-625.	2.4	2
50	Glioma-associated epilepsy: toward mechanism-based treatment. <i>Translational Cancer Research</i> , 2017, 6, S337-S341.	1.0	2
51	International practice variation in perioperative laboratory testing in glioblastoma patientsâ€“a retrospective cohort study. <i>Acta Neurochirurgica</i> , 2022, 164, 385-392.	1.7	1
52	Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2967.	3.7	1
53	Response to: â€œPrognostic relevance of epilepsy at presentation in lower-grade gliomasâ€“ <i>Neuro-Oncology</i> , 2016, 18, 1327-1328.	1.2	0
54	Complications, compliance and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	0